162 related articles for article (PubMed ID: 32068354)
21. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
Timmermann S; Hall A
Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
23. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Aug; 41(4):375-87. PubMed ID: 25077917
[TBL] [Abstract][Full Text] [Related]
24. Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
Gibiansky L; Ng CM; Gibiansky E
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38639818
[TBL] [Abstract][Full Text] [Related]
25. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
[TBL] [Abstract][Full Text] [Related]
26. Target-mediated exposure enhancement: a previously unexplored limit of TMDD.
Glassman PM; Muzykantov VR
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):411-420. PubMed ID: 32488574
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
28. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
Shah DK; Balthasar JP
Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
[TBL] [Abstract][Full Text] [Related]
29. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
[TBL] [Abstract][Full Text] [Related]
30. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I.
Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D
Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996
[TBL] [Abstract][Full Text] [Related]
32. Target-mediated drug disposition modeling of an anti-TFPI antibody (MG1113) in cynomolgus monkeys to predict human pharmacokinetics and pharmacodynamics.
Kwak EY; Kim MJ; Park JH; Jung HW; Jung ME
J Thromb Haemost; 2021 Jun; 19(6):1425-1435. PubMed ID: 33448093
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
[TBL] [Abstract][Full Text] [Related]
34. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy After Single and Multiple Dosings of LY3016859 in Healthy Subjects and Patients With Diabetic Nephropathy.
Sloan-Lancaster J; Raddad E; Deeg MA; Eli M; Flynt A; Tumlin J
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):759-772. PubMed ID: 29385323
[TBL] [Abstract][Full Text] [Related]
36. Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Rα, in Atopic Dermatitis Patients and Normal Volunteers.
Kovalenko P; DiCioccio AT; Davis JD; Li M; Ardeleanu M; Graham N; Soltys R
CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):617-624. PubMed ID: 27778477
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
38. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
[TBL] [Abstract][Full Text] [Related]
40. Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.
Ahmed S; Ellis M; Li H; Pallucchini L; Stein AM
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):287-304. PubMed ID: 31037615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]